The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice

Cellular and Molecular Immunology

Volumn 7, Issue 5, 2010, Pages 381-388

  Ma, Fang ^a   Zhang, Jianhua ^a   Zhang, Jian ^a   Zhang, Cai ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

antitumor therapy; DC vaccine; melanoma; TLR; TLR7 8 agonist

Indexed keywords

DENDRITIC CELL VACCINE; GARDIQUIMOD; IMIQUIMOD; INTERLEUKIN 12; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENTIATION; IMMUNE RESPONSE; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOTOXICITY; DRUG EFFECT; IMMUNIZATION; IMMUNOLOGY; MELANOMA; PATHOLOGY; SPLEEN;

MURINAE; MUS;

AMINOQUINOLINES; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; IMIDAZOLES; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; SPLEEN; TOLL-LIKE RECEPTOR 7;

EID: 77957680668     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.30     Document Type: Article

References (26)

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216. (Pubitemid 34293424)
2. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2006; 84: 712-725. (Pubitemid 44328063)
3. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J Infect Chemother 2008; 14: 86-92. (Pubitemid 351624472)
4. Takeda K, Kaisho T, Akira. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
5. Heil F, Hemmi H, Hochrein F, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004; 303: 1526-1529. (Pubitemid 38314424)
6. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101: 5598-5603. (Pubitemid 38481202)
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 12: 4783-4801.
8. Wenzel J, Tormo D, Tüting T. Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. Hand Exp Pharmacol 2008; 183: 201-220.
9. Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 2003; 3: 373-385. (Pubitemid 36621794)
10. Sato A, Iwasaki A. Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc Natl Acad Sci USA 2004; 101: 16274-16279. (Pubitemid 39552835)
11. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens ML et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42: 789-794. (Pubitemid 28216355)
12. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005; 175: 1983-1990. (Pubitemid 41023106)
13. Smits EL, Ponsaerts P, Berneman ZN, van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13: 859-875.
14. Prins RM, Craft N, Bruhn KW, Khan-Farooqi HK, Koya RC, Stripecke R et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immnol 2006; 176: 157-163.
15. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204: 1441-1451. (Pubitemid 46919881)
16. Larangé A, Antonios D, Pallardy M, Kerdine-Römer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol 2009; 85: 673-683.
17. Caron G, Duluc D, Frémaux I, Jeannin P, David C, Gascan H et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005; 175: 1551-1557. (Pubitemid 41023056)
18. Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, Mollet IG et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 2009; 129: 2676-2685.
19. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cell results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175: 1636-1642. (Pubitemid 41023066)
20. + regulatory T cell function. Science 2005; 309: 1380-1384.
21. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-1149. (Pubitemid 37045392)
22. Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266-1276. (Pubitemid 38651103)
23. Marin-Esteban V, Abdul M, Charron D, Haziot A, Mooney N. Dendritic cells differentiated in the presence of a single-stranded viral RNA sequence conserved their ability to activate CD4 T lymphocytes but lose their capacity for Th1 polarization. Clin Vaccine Immunol 2008; 15: 954-962. (Pubitemid 351967008)
24. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-4537. (Pubitemid 34441357)
25. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 2007; 6: 835-847. (Pubitemid 47607857)
26. + cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother 2009; 58: 575-587.